PRESS RELEASE published on 12/03/2025 at 08:00, 5 months 7 days ago Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radiodiagnostic Candidate 68Ga-PentixaFor in Hypertension Pentixapharm advances regulatory preparations for Phase 3 PANDA study with radiodiagnostic candidate 68Ga-PentixaFor in hypertension. FDA provides feedback on clinical protocol FDA Feedback Hypertension Pentixapharm Phase 3 PANDA Study 68Ga-PentixaFor
BRIEF published on 11/12/2025 at 08:05, 5 months 28 days ago Pentixapharm publie ses résultats financiers pour les 9 premiers mois de 2025 Perte Financière Revenu Pentixapharm Résultats À 9 Mois Ajustement Des Directives
BRIEF published on 11/12/2025 at 08:05, 5 months 28 days ago Pentixapharm Reports 9-Month Financial Results for 2025 Revenue Financial Loss Guidance Adjustment Pentixapharm 9-Month Results
PRESS RELEASE published on 11/12/2025 at 08:00, 5 months 28 days ago Pentixapharm Publishes 9-Month Figures for 2025 Pentixapharm announces 9-month figures for 2025, reports €12.7 million loss. Adjusted guidance projects approximately €18 million loss for the fiscal year. New financial statements available on website Financial Statements 2025 Loss 9-month Figures Pentixapharm
BRIEF published on 11/10/2025 at 08:05, 6 months ago Pentixapharm to Release Financial Results for Q3 and Nine Months of 2025 Financial Results Oncology Biotech Radiopharmaceuticals Pentixapharm
BRIEF published on 11/10/2025 at 08:05, 6 months ago Pentixapharm publiera ses résultats financiers pour le troisième trimestre et les neuf premiers mois de 2025. Résultats Financiers Biotechnologie Oncologie Produits Radiopharmaceutiques Pentixapharm
PRESS RELEASE published on 11/10/2025 at 08:00, 6 months ago Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025 Pentixapharm Holding AG to release Third Quarter and First Nine Months 2025 Financial Results on November 12, 2025. Conference call and webcast to follow Financial Results Conference Call Berlin Radiopharmaceuticals Pentixapharm
BRIEF published on 11/06/2025 at 20:00, 6 months 3 days ago Pentixapharm Holding AG réduit ses prévisions de pertes pour 2025 Développement Clinique Prévisions Financières Réduction Des Coûts Industrie Biotechnologique Optimisation Stratégique
BRIEF published on 11/06/2025 at 20:00, 6 months 3 days ago Pentixapharm Holding AG Reduces Projected Loss for 2025 Biotech Industry Clinical Development Cost Reduction Financial Forecast Strategic Optimization
PRESS RELEASE published on 11/06/2025 at 19:55, 6 months 3 days ago EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm significantly reduces projected loss for financial year 2025 Pentixapharm Holding AG significantly reduces projected loss for financial year 2025 due to clinical development program realignment Clinical Development Realignment Pentixapharm Financial Year 2025 Projected Loss
Published on 05/09/2026 at 01:30, 1 day 12 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 14 hours ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/10/2026 at 14:00, 18 minutes ago MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 2 hours 33 minutes ago Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 19 hours 13 minutes ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 17 hours ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day 19 hours ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/07/2026 at 19:15, 2 days 19 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 19 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 19 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 19 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 19 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
